Multiplexed imaging in cancer diagnosis: Applications and future advances

The Lancet Oncology

Volumn 11, Issue 6, 2010, Pages 589-595

  Kobayashi, Hisataka ^a   Longmire, Michelle R ^a   Ogawa, Mikako ^a   Choyke, Peter L ^a   Kawamoto, Satomi ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN G; INDIUM 111; INDOCYANINE GREEN; IODINE 123; RADIOISOTOPE; TECHNETIUM 99M; THALLIUM 201; TRASTUZUMAB;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SCREENING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HEAD AND NECK CANCER; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CONTRAST MEDIA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953541131     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70009-7     Document Type: Review

References (63)

1. Frangioni JV New technologies for human cancer imaging. J Clin Oncol 2008, 26:4012-4021.
2. Ben-Haim S, Ell P 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009, 50:88-99.
3. Ford EC, Herman J, Yorke E, Wahl RL 18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy. J Nucl Med 2009, 50:1655-1665.
4. Mawlawi O, Townsend DW Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009, 36(suppl 1):S15-S29.
5. von Schulthess GK, Steinert HC, Hany TF Integrated PET/CT: current applications and future directions. Radiology 2006, 238:405-422.
6. Devaraj A, Cook GJ, Hansell DM PET/CT in non-small cell lung cancer staging-promises and problems. Clin Radiol 2007, 62:97-108.
7. Eschmann SM, Bitzer M, Paulsen F, et al. The benefit of functional-anatomical imaging with [18F]fluorodeoxyglucose utilizing a dual-head coincidence gamma camera with an integrated X-ray transmission system in non-small cell lung cancer. Nucl Med Commun 2004, 25:909-915.
8. Gilman MD, Aquino SL State-of-the-Art FDG-PET imaging of lung cancer. Semin Roentgenol 2005, 40:143-153.
9. Hicks RJ Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 2009, 50(suppl 1):31S-42S.
10. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005, 236:1011-1019.
11. Kaijzel EL, Snoeks TJ, Buijs JT, van der Pluijm G, Lowik CW Multimodal imaging and treatment of bone metastasis. Clin Exp Metastasis 2009, 26:371-379.
12. Koyama Y, Talanov VS, Bernardo M, et al. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging 2007, 25:866-871.
13. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008, 14:459-465.
14. Pichler BJ, Judenhofer MS, Wehrl HF PET/MRI hybrid imaging: devices and initial results. Eur Radiol 2008, 18:1077-1086.
15. Kobayashi H, Koyama Y, Barrett T, et al. Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano 2007, 1:258-264.
16. Ogawa M, Regino CA, Seidel J, et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem 2009, 20:2177-2184.
17. McBiles M, Lambert AT, Cote MG, Kim SY Sestamibi parathyroid imaging. Semin Nucl Med 1995, 25:221-234.
18. Neumann DR, Obuchowski NA, Difilippo FP Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med 2008, 49:2012-2017.
19. Shih WJ, Stipp V, Magoun S, Ain KB, Pulmano C Medullary thyroid carcinoma imaged by Tc-99m MIBI SPECT and Tl-201 chloride/Tc-99m pertechnetate subtraction SPECT. Clin Nucl Med 1996, 21:213-217.
20. Antunes ML, Johnson LL, Seldin DW, et al. Diagnosis of right ventricular acute myocardial infarction by dual isotope thallium-201 and indium-111 antimyosin SPECT imaging. Am J Cardiol 1992, 70:426-431.
21. Johnson LL, Lerrick KS, Coromilas J, et al. Measurement of infarct size and percentage myocardium infarcted in a dog preparation with single photon-emission computed tomography, thallium-201, and indium 111-monoclonal antimyosin Fab. Circulation 1987, 76:181-190.
22. Johnson LL, Seldin DW, Keller AM, et al. Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic risk. Circulation 1990, 81:37-45.
23. Schoeder H, Topp H, Friedrich M, Jatzkewitz A, Roser M Thallium and indium antimyosin dual-isotope single-photon emission tomography in acute myocardial infarction to identify patients at further ischaemic risk. Eur J Nucl Med 1994, 21:415-422.
24. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 2007, 9:1021-1029.
25. Koh DM, Collins DJ Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007, 188:1622-1635.
26. Padhani AR Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002, 16:407-422.
27. Jacobs MA, Pan L, Macura KJ Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer. Semin Roentgenol 2009, 44:111-122.
28. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004, 22:275-282.
29. Schmidt GP, Reiser MF, Baur-Melnyk A Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 2009, 70:393-400.
30. Ramanujan VK, Zhang JH, Biener E, Herman B Multiphoton fluorescence lifetime contrast in deep tissue imaging: prospects in redox imaging and disease diagnosis. J Biomed Opt 2005, 10:051407.
31. Elson D, Requejo-Isidro J, Munro I, et al. Time-domain fluorescence lifetime imaging applied to biological tissue. Photochem Photobiol Sci 2004, 3:795-801.
32. Weissleder R A clearer vision for in vivo imaging. Nat Biotechnol 2001, 19:316-317.
33. Hama Y, Urano Y, Koyama Y, et al. A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res 2007, 67:2791-2799.
34. Urano Y, Asanuma D, Hama Y, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009, 15:104-109.
35. Ogawa M, Kosaka N, Choyke PL, Kobayashi H In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 2009, 69:1268-1272.
36. Bybel B, Brunken RC, Shah SN, Wu G, Turbiner E, Neumann DR PET and PET/CT imaging: what clinicians need to know. Cleve Clin J Med 2006, 73:1075-1087.
37. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002, 43:1339-1342.
38. Ay MR, Zaidi H Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. Eur J Nucl Med Mol Imaging 2006, 33:1301-1313.
39. Domingues RC, Carneiro MP, Lopes FC, Domingues RC, da Fonseca LM, Gasparetto EL Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. AJR Am J Roentgenol 2009, 192:1012-1020.
40. Lauenstein TC, Semelka RC Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging 2006, 24:489-498.
41. Beyer T, Weigert M, Quick HH, et al. MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging 2008, 35:1142-1146.
42. Hofmann M, Pichler B, Scholkopf B, Beyer T Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging 2009, 36(suppl 1):S93-104.
43. Hofmann M, Steinke F, Scheel V, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med 2008, 49:1875-1883.
44. Martinez-Moller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 2009, 50:520-526.
45. Zaidi H, Montandon ML, Slosman DO Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography. Med Phys 2003, 30:937-948.
46. Lehmann S, Stiehl DP, Honer M, et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci USA 2009, 106:14004-14009.
47. Yong KT Mn-doped near-infrared quantum dots as multimodal targeted probes for pancreatic cancer imaging. Nanotechnology 2009, 20:015102.
48. Berman DS, Kiat H, Van Train K, Friedman JD, Wang FP, Germano G Dual-isotope myocardial perfusion SPECT with rest thallium-201 and stress Tc-99m sestamibi. Cardiol Clin 1994, 12:261-270.
49. Kiat H, Germano G, Friedman J, et al. Comparative feasibility of separate or simultaneous rest thallium-201/stress technetium-99m-sestamibi dual-isotope myocardial perfusion SPECT. J Nucl Med 1994, 35:542-548.
50. Matsunari I, Kanayama S, Yoneyama T, et al. Electrocardiographic-gated dual-isotope simultaneous acquisition SPECT using 18F-FDG and 99mTc-sestamibi to assess myocardial viability and function in a single study. Eur J Nucl Med Mol Imaging 2005, 32:195-202.
51. Weinmann P, Faraggi M, Moretti JL, Hannequin P Clinical validation of simultaneous dual-isotope myocardial scintigraphy. Eur J Nucl Med Mol Imaging 2003, 30:25-31.
52. Kosaka N, Ogawa M, Sato N, Choyke PL, Kobayashi H In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol 2009, 129:2818-2822.
53. Barrett T, Koyama Y, Hama Y, et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 2007, 13:6639-6648.
54. Brockmann C, Jochum S, Sadick M, et al. Dual-energy CT angiography in peripheral arterial occlusive disease. Cardiovasc Intervent Radiol 2009, 32:630-637.
55. Chen X, Gilkeson RC, Fei B Automatic 3D-to-2D registration for CT and dual-energy digital radiography for calcification detection. Med Phys 2007, 34:4934-4943.
56. Tran DN, Straka M, Roos JE, Napel S, Fleischmann D Dual-energy CT discrimination of iodine and calcium: experimental results and implications for lower extremity CT angiography. Acad Radiol 2009, 16:160-171.
57. Thieme SF, Johnson TR, Lee C, et al. Dual-energy CT for the assessment of contrast material distribution in the pulmonary parenchyma. AJR Am J Roentgenol 2009, 193:144-149.
58. Pontana F, Faivre JB, Remy-Jardin M, et al. Lung perfusion with dual-energy multidetector-row CT (MDCT): feasibility for the evaluation of acute pulmonary embolism in 117 consecutive patients. Acad Radiol 2008, 15:1494-1504.
59. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008, 248:643-654.
60. Hassan M, Riley J, Chernomordik V, et al. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 2007, 6:229-236.
61. Wu AM, Senter PD Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137-1146.
62. Weissleder R, Pittet MJ Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
63. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000, 18:321-325.